GSK, Jemperli and european union
GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...
Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...
J&J agreed to buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of reentry into neuroscience by large ...
The British pharma giant announced plans to acquire IDRx, a Plymouth-based biotech working on precision treatments for ...
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...
The anti-vaccine movement in the U.S. has gained momentum with President-elect Donald Trump's nomination of Robert F. Kennedy ...
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will ...
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
Shares of GSK PLC GSK inched up 0.59% to £13.64 Thursday, on what proved to be an all-around positive trading session for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback